Show/Hide Menu
Hide/Show Apps
Logout
Türkçe
Türkçe
Search
Search
Login
Login
OpenMETU
OpenMETU
About
About
Open Science Policy
Open Science Policy
Open Access Guideline
Open Access Guideline
Postgraduate Thesis Guideline
Postgraduate Thesis Guideline
Communities & Collections
Communities & Collections
Help
Help
Frequently Asked Questions
Frequently Asked Questions
Guides
Guides
Thesis submission
Thesis submission
MS without thesis term project submission
MS without thesis term project submission
Publication submission with DOI
Publication submission with DOI
Publication submission
Publication submission
Supporting Information
Supporting Information
General Information
General Information
Copyright, Embargo and License
Copyright, Embargo and License
Contact us
Contact us
ASSOCIATION OF FLT3 AND NPM1 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH METABOLOMIC PATTERNS DETERMINED BY MASS SPECTROMETRY
Download
Selin GEREKCI YEŞİLYURT Doktora Tezi 18.09.2022.pdf
Date
2022-8-29
Author
Gerekci Yeşilyurt, Selin
Metadata
Show full item record
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
.
Item Usage Stats
253
views
161
downloads
Cite This
Acute Myeloid Leukemia is a hematological cancer with high phenotypic and genotypic heterogeneity. Patients diagnosed with AML are categorized into risk groups based on cytogenetic and molecular abnormality tests, which determine the specific treatment regimes. Since risk status determination takes significant amount of time and some emergency patients require immediate treatment, a method to provide fast clinical data that will be the basis for initial treatment regime is needed in the medical community. Objective of the proposed work is to discover patterns associated with FLT3-ITD and NPM1 mutations in Acute Myeloid Leukemia patients, which will provide a fast clinical method for the proper first-response treatment. The rationale for the hypothesis is based on the previous studies which indicate a link between NPM1 and FLT3-ITD mutations with glucose and amino acid metabolism. NPM1 and FLT3 mutations were chosen based on their high frequency in AML patients and their essential role in risk group determination. Metabolic pattern determination of the mutations was achieved by LC-MS/MS measurements of amino acid and acyl carnitine panels that are highly associated with amino acid and glucose metabolism. After preprocessing of the raw data, univariate (ANOVA) and multivariate analyses (PCA and PLS-DA) were performed to define class discrimination between sample groups. The remarkable analytes that have significant power in the discrimination were determined by VIP analysis. The developed model was validated with K-Fold cross validation method and permutation test. The most significant pathways in class discrimination were identified with pathway analysis. Visualization was accomplished via Metaboanalyst 5.0 software. Principal Component Analysis (PCA) showed that 79% of the total variance of the sample groups was explained by the model. In order to increase class discrimination, Partial Least Squares-Discriminant Analysis (PLS-DA) was performed. R2Y and Q2 were found as 0.845 and 0.619, respectively. PLS-DA model was validated with K-fold analysis and permutation test. In all the validation experiments carried out, a low cross-validation error was observed. In VIP analysis, the most significant analytes that cause the class discrimination were found as C0 carnitine, glutamic acid, aspartic acid, tryptophan, and histidine, respectively. In the pathway enrichment analysis performed with these analytes, aminoacyl t-RNA biosynthesis, arginine biosynthesis, valine-leucine-isoleucine biosynthesis, alanine-aspartate-glutamate metabolism, histidine metabolism and arginine-proline metabolism were found as statistically significant pathways responsible for the class discrimination. In conclusion, a preliminary model based on the targeted metabolomics approach was developed for the prediction of mutation status of NPM1 and FLT3 proteins in AML patients. Proposed model has a high fit value, validity, and strong predictive power. The reliability and validity of the model can be further increased by future multicenter studies.
Subject Keywords
Hematological Malignancies
,
Acute Myeloid Leukemia
,
Metabolomics
,
Multivariate Analysis
,
Mass Spectrometry
URI
https://hdl.handle.net/11511/99539
Collections
Graduate School of Natural and Applied Sciences, Thesis
Suggestions
OpenMETU
Core
Identification of polymorphisms on the MDR1 gene among Turkish population and their effects on multidrug resistance in acute leukemia patients
Kaya, P; Gündüz, Ufuk; Arpaci, F; Ural, AU; Guran, S (2005-09-01)
Multidrug-resistance (MDR) phenotype is a serious limitation to the effective chemotherapeutic treatment of many cancer types, including leukemia. One of the most important proteins, the over-expression of which is responsible for the multidrug-resistance phenotype in many cancer types, is P-glycoprotein. This protein is the product of the MDR1 gene. In previous studies, single-nucleotide polymorphisms (SNPs) C3435T, G2677T, and T-129C in the MDR1 gene were shown to be correlated with lower P-glycoprotein e...
Evaluation of metabolite variation between acute lymphoblastic leukemia (ALL) and chronic myeloidleukemia (CML) cell lines via triple quadrupole LC-MS
Pekşen, Ceren; Özen, Can.; Department of Biotechnology (2019)
Hematologic cancers have two origins: myeloid and lymphoid. While lymphatic leukemia, originate from the lymphoid cell line, acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) originate from the myeloid cell line. CML is granulocyte cancer and in this disease, as well as granulocytes, the number of cells that cause blood clotting, which are called platelets, may increase in the blood. In CML, a non-hereditary genetic abnormality, Philadelphia chromosome, where a structural change occurs in chro...
Studies directed towards The synthesis Of İmatinib Mesylate ((Gleevec), 4-(4-Methyl-Piperazin-1- Ylmethyl)-N-[4- Methyl-3-(4-Pyridin-3-Yl-Pyrimidin-2- Ylamino)-Phenyl]- Benzamide Methanesulfonate) Analogs
Günay, Neşet Batuhan; Demir, Ayhan Sıtkı; Department of Chemistry (2008)
Imatinib mesylate is indicated for the treatment of chronic myeloid leukemia (CML) and unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). By the application of this anticancer drug, problems occurs in terms of stability and activity. Computer assisted design (CAD) works showed that the modification of the B and C part molecule can increase the effectivity of the drug. The new derivatives of the drug will be obtained to change some part of the B and C segments. The total synthes...
Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells
Donmez, Yaprak; Akhmetova, Laila; Iseri, Ozlem Darcansoy; Kars, Meltem Demirel; Gündüz, Ufuk (2011-04-01)
One of the major problems of cancer chemotherapy is the development of multidrug resistance (MDR) phenotype. Among the numerous mechanisms of MDR, a prominent one is the increased expression of membrane transporter proteins, the action of which leads to decreased intracellular drug concentration and cytotoxicity of drugs. Among them, P-gp and MRP1, encoded by MDR1 and MRP1 genes, respectively, have been associated with MDR phenotype. Chemical modulators can be used to reverse MDR. These chemicals can either...
Network-based in silico modeling for drug repurposing and in vitro validation in hepatocellular carcinoma
Nalbat, Esra; Tunçbağ, Nurcan; Cetin-Atalay, Rengul (Orta Doğu Teknik Üniversitesi Enformatik Enstitüsü; 2022-10)
Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and a leading cause of death worldwide. The hyperactivated cell survival signaling pathways cause resistance to conventional chemotherapeutics so that targeted therapies could extend patient survival for only a few months. Furthermore, there are limited chemotherapeutics for HCC patients due to impaired liver functions. Thus, it is vital to determine repurposed drugs and drug combinations in HCC treatment.
Citation Formats
IEEE
ACM
APA
CHICAGO
MLA
BibTeX
S. Gerekci Yeşilyurt, “ASSOCIATION OF FLT3 AND NPM1 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH METABOLOMIC PATTERNS DETERMINED BY MASS SPECTROMETRY,” Ph.D. - Doctoral Program, Middle East Technical University, 2022.